ClinicalTrials.gg
CompletedNCT02484690AVENUEUpdated Nov 12, 2020Results posted

A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)

A Phase 2 interventional study of Faricimab and Ranibizumab in Choroidal Neovascularization, sponsored by Hoffmann-La Roche. Completed at 52 sites in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2020-11-12.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
273
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 45 studies testing ranibizumab in Choroidal Neovascularization — none open to participants now, none under way, none of them phase 3. Ranibizumab · Choroidal Neovascularization.

Enrollment
9th of 45
273 · median 62
Started
2015
with 2 others
Phase 2
10 of 45
none open now
Registered
44th of 45
by date
Lead sponsor
1 of 45
Hoffmann-La Roche

Among the 45 studies testing ranibizumab in Choroidal Neovascularization, this one is the 9th largest by enrollment, is one of 3 that started in 2015, is one of 10 in phase 2, and was the 44th registered.

Choroidal Neovascularization

214 studies on the registry are indexed under Choroidal Neovascularization; 12 are open to participants now.

Browse Choroidal Neovascularization studies →

Open to participants now

None of the 45 studies testing ranibizumab in Choroidal Neovascularization is open now. The open studies under Choroidal Neovascularization, anywhere →

About ranibizumab

Ranibizumab: first FDA approval 2006 (LUCENTIS), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 6 Choroidal Neovascularization studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 50 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 45 studies testing ranibizumab in Choroidal Neovascularization as a file.
02

Study summary

This multiple-center, multiple-dose and regimen, randomized, double-masked active comparator-controlled, double-masked, five parallel group, 36-week study will evaluate the efficacy, safety, tolerability, and pharmacokinetics of faricimab (RO6867461) in participants with choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD).

The study was designed to allow the evaluation of RO6867461 in a treatment-naive population (comparison of Arms A, B, C, and D) and an anti-VEGF-incomplete responder population that met a predefined criterion at Week 12 (comparison between Arms A and E). Only one eye per participant was chosen as the study eye.

03

Conditions studied

  • Choroidal Neovascularization
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Treatment-naive with CNV secondary to AMD, with subfoveal CNV or juxtafoveal CNV with a subfoveal component related to the CNV activity by FFA or SD-OCT
  • Active CNV

Exclusion criteria

Exclusion Criteria:

  • CNV due to causes other than AMD
  • Subretinal hemorrhage, fibrosis, or atrophy involving either the fovea or more than 50% of the total lesion area
  • Cataract surgery within 3 months of baseline, or any other previous intraocular surgery
  • Major illness or surgery within 1 month prior to Screening
  • Glycosylated () above 7.5%
  • Uncontrolled blood pressure
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
273 participants (actual)

Study arms

  • Active comparator
    Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)

    Participants will receive ranibizumab, 0.5 milligrams (mg) intravitreal (IVT) Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.

    Drug: Ranibizumab

  • Experimental
    Arm B: Faricimab, 1.5 mg Q4W

    Participants will receive faricimab 1.5 mg IVT Q4W up to Week 32 (total 9 injections). The final study visit will take place at Week 36.

    Drug: Faricimab

  • Experimental
    Arm C: Faricimab, 6 mg Q4W

    Participants will receive faricimab 6 mg IVT Q4W up to Week 32 (9 injections). The final study visit will take place at Week 36.

    Drug: Faricimab

  • Experimental
    Arm D: Faricimab, 6 mg Every 4-8 weeks

    Participants will receive faricimab, 6 mg IVT Q4W up to Week 12 (4 injections), followed by 6 mg IVT every 8 weeks up to Week 28 (2 injections). On Weeks 16, 24, and 32, participants received the sham procedure in order to maintain masking. The final study visit will take place at Week 36.

    Drug: Faricimab · Drug: Sham Procedure

  • Experimental
    Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W

    Participants will receive ranibizumab, 0.5 mg IVT Q4W up to Week 8 (3 injections), followed by faricimab, 6 mg IVT Q4W up to Week 32 (6 injections). The final study visit will take place at Week 36.

    Drug: Faricimab · Drug: Ranibizumab

Interventions

  • Faricimab will be administered as per the regimen specified in the individual arm.

    Also known as: RO6867461, RG7716

  • Ranibizumab will be administered as per the regimen specified in the individual arm.

    Also known as: Lucentis

  • DrugSham Procedure

    The sham is a procedure that mimics an intravitreal injection, but involves the blunt end of an empty syringe (without a needle) being pressed against the anesthetized eye. It will be administered to participants in treatment arm D at applicable visits to maintain masking.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  2. Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Weeks 12 and 36

Secondary outcomes

  1. Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Baseline, Week 36

  2. Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Weeks 12 and 36

  3. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Week 36

  4. Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Week 36

  5. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Week 36

  6. Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders

    Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

    Time frame: Week 36

  7. Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants

    Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  8. Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders

    Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Weeks 12 and 36

  9. Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants

    Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  10. Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders

    Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Weeks 12 and 36

  11. Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants

    The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

    Time frame: Baseline, Week 36

  12. Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders

    The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

    Time frame: Weeks 12 and 36

  13. Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants

    The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  14. Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

    The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Weeks 12 and 36

  15. Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants

    The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  16. Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

    The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Weeks 12 and 36

  17. Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants

    The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

    Time frame: Baseline, Week 36

  18. Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

    The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).

    Time frame: Weeks 12 and 36

  19. Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants

    This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. AEs are categorized as any AEs, ocular AEs occurring in the study eye or fellow eye, systemic AEs, serious AEs, AEs related to treatment with study drug, AEs leading to discontinuation (withdrawal) of treatment with study drug, and AEs with fatal outcome. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.

    Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  20. Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants

    The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

    Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  21. Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants

    The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

    Time frame: From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  22. Number of Participants With Abnormal Systolic Blood Pressure, in All Participants

    Abnormal systolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<70 (low) to \>140 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

    Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  23. Number of Participants With Abnormal Diastolic Blood Pressure, in All Participants

    Abnormal diastolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>90 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

    Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  24. Number of Participants With Abnormal Heart Rate, in All Participants

    Abnormal heart rate (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>100 (high) beats per minute. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

    Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  25. Number of Participants With Abnormal Body Temperature, in All Participants

    Abnormal body temperature (supine) was defined as any value outside of the standard reference range, from \<36.5 (low) to \>37.5 (high) degrees Celsius. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

    Time frame: Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)

  26. Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants

    Clinical laboratory tests for hematology and coagulation parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Abs. = absolute count; Corp. = corpuscular; Ery. = erythrocyte; INR = International Normalized Ratio

    Time frame: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)

  27. Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants

    Clinical laboratory tests for blood chemistry parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. GGT = gamma-glutamyltransferase; SGOT/AST = serum glutamic oxaloacetic transaminase / aspartate aminotransferase; SGPT/ALT = serum glutamic pyruvic transaminase / alanine aminotransferase

    Time frame: Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)

  28. Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants

    Intraocular pressure is the fluid pressure inside the eye. The method used to measure intraocular pressure (e.g., Goldmann tonometry) for each participant was to be applied consistently by the investigator throughout the study. On the day of dosing, intraocular pressure was monitored at 30 minutes post-treatment administration, and if intraocular pressure was ≥30 mmHg in the study eye, it was reassessed at 1 hour post-treatment administration.

    Time frame: Baseline, 0.5 hours postdose on Day 1, predose and 0.5 hours postdose at Weeks 4, 8, 12, 16, 20, 24, 28, and 32, and at Weeks 1, 13, and 36

  29. Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint

    Blood samples were obtained for measurement of anti-faricimab antibodies by a validated enzyme-linked immunosorbent assay (ELISA).

    Time frame: Baseline, Predose (0 hour) on Days 1, 28, 84, 112, 168, and 252 or early termination (up to 36 weeks)

  30. Mean Plasma Concentration of Faricimab Over Time, in All Participants

    Plasma concentrations of faricimab were measured by a specific validated enzyme-linked immunoabsorbent assay (ELISA) only from samples of participants randomized to receive faricimab. Baseline was defined as the last non-missing predose assessment. The lower limit of quantification (LLOQ) for the faricimab assay was 0.800 nanograms per millilitre (ng/mL). Values below the limit of quantification were imputed as LLOQ divided by 2.

    Time frame: Predose (on days when treatment was administered) at Baseline and Weeks 4, 12, 13, 16, 24, and 36

  31. Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants

    The concentration of free VEGF was determined in plasma samples using an enzyme-linked immunosorbent assay (ELISA) method. The lower limit of quantification (LLOQ) of the assay was 15.6 picograms per millilitre (pg/mL). Plasma free VEGF concentrations below the limit of quantification were imputed as LLOQ divided by 2.

    Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36

  32. Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants

    Total Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.09 nanograms per millilitre (ng/mL). Plasma total Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

    Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36

  33. Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants

    Free Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.9 nanograms per millilitre (ng/mL). Plasma free Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

    Time frame: Baseline, Weeks 4, 12, 13, 16, 24, and 36

07

Results

Posted Oct 9, 2020
Limitations and caveats
The small number of participants per cohort only allows detection of large differences in outcomes; not designed to show noninferiority of faricimab relative to ranibizumab. The short duration further limits information on long-term visual potential.

Participant flow

Participant flow — Overall Study
MilestoneArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Started6846394664
Received at least one dose of study drug6746394664
Completed6440364458
Not completed46326
Withdrew: Adverse event13005
Withdrew: Death00001
Withdrew: Withdrawal by subject13120
Withdrew: Physician decision20100
Withdrew: Lost to follow-up00100

Outcome measures

PrimaryMean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · BCVA Letters
Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants
BCVA LettersArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants7.61 (5.43 to 9.80)9.18 (6.54 to 11.83)6.02 (3.24 to 8.80)6.10 (3.56 to 8.64)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.5244 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 1.57 · 80% CI -1.60 to 4.74The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.5308 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -1.59 · 80% CI -4.86 to 1.67The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.5309 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -1.51 · 80% CI -4.62 to 1.59The mean difference was calculated as Arm D minus Arm A.
PrimaryMean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The primary analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Weeks 12 and 36
Reported as:
Least squares mean · BCVA Letters
Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders
BCVA LettersArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders1.72 (-0.69 to 4.13)0.04 (-2.27 to 2.35)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.3034 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -1.68 · 80% CI -3.77 to 0.42The mean difference was calculated as Arm E minus Arm A.
SecondaryPercentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · Percentage of Participants
Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Percentage of Participants Gaining Greater Than or Equal to (≥) 15 Letters From Baseline in BCVA Letter Score at Week 36, in Treatment-Naive Participants31.0 (24.1 to 38.8)36.6 (27.6 to 46.7)27.9 (19.6 to 38.0)23.7 (16.5 to 32.7)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Generalized Estimating Equations Model · p = 0.5527 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 5.63 · 80% CI -6.52 to 17.77The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Generalized Estimating Equations Model · p = 0.7382 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -3.09 · 80% CI -14.95 to 8.76The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Generalized Estimating Equations Model · p = 0.3932 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -7.32 · 80% CI -18.32 to 3.67The mean difference was calculated as Arm D minus Arm A.
SecondaryPercentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Weeks 12 and 36
Reported as:
Number · Percentage of Participants
Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Percentage of Participants Gaining ≥15 Letters From Week 12 in BCVA Letter Score at Week 36, in Anti-VEGF Incomplete Responders5.71 (0.69 to 10.74)0.00 (0.00 to 0.00)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Fisher Exact · p = 0.2328 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in percentage of participants: -5.71 · 80% CI -10.74 to -0.69The difference was calculated as Arm E minus Arm A.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Week 36
Reported as:
Least squares mean · Percentage of Participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Treatment-Naive Participants49.5 (41.6 to 57.4)49.0 (39.2 to 58.8)39.4 (29.8 to 49.9)41.8 (32.8 to 51.4)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Generalized Estimating Equations Model · p = 0.9581 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -0.52 · 80% CI -13.26 to 12.22The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Generalized Estimating Equations Model · p = 0.3166 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -10.08 · 80% CI -22.99 to 2.82The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Generalized Estimating Equations Model · p = 0.4244 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -7.68 · 80% CI -20.01 to 4.64The mean difference was calculated as Arm D minus Arm A.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Week 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Percentage of Participants With BCVA Snellen Equivalent of 20/40 or Better at Week 36, in Anti-VEGF Incomplete Responders22.86 (13.76 to 31.95)16.22 (8.45 to 23.98)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Fisher Exact · p = 0.5586 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in percentage of participants: -6.64 · 80% CI -18.60 to 5.32The difference was calculated as Arm E minus Arm A.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. The outcome measure was analyzed using a Generalized Estimating Equations Model. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Week 36
Reported as:
Least squares mean · Percentage of Participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Treatment-Naive Participants7.7 (4.4 to 13.2)8.7 (4.6 to 16.0)15.8 (9.6 to 25.0)8.8 (4.7 to 15.9)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Generalized Estimating Equations Model · p = 0.8536 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 1.00 · 80% CI -5.93 to 7.93The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Generalized Estimating Equations Model · p = 0.2303 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 8.14 · 80% CI -0.56 to 16.83The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Generalized Estimating Equations Model · p = 0.8406 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 1.08 · 80% CI -5.79 to 7.95The mean difference was calculated as Arm D minus Arm A.
SecondaryPercentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders

Best corrected visual acuity (BCVA) at a starting test distance of 4 meters was measured using a set of three Precision VisionTM or Lighthouse distance acuity charts (modified ETDRS Charts 1, 2, and R) prior to dilating eyes by a trained and certified visual acuity examiner masked to study drug arm assignment. The BCVA examiner was masked to study eye and treatment assignment and only performed the refraction and BCVA assessment, but was not allowed to perform any other tasks involving direct care. The BCVA examiner was also masked to the BCVA letter scores of a participant's previous visits and could only know the participant's refraction data from previous visits. The BCVA letter score ranges from 0 to 100 (best score attainable), and a gain in BCVA letter score from baseline indicates an improvement in visual acuity. Missing values were not imputed; it was assumed that the data were missing at random.

Time frame:
Week 36
Reported as:
Number · Percentage of Participants
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders
Percentage of ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Percentage of Participants With BCVA Snellen Equivalent of 20/200 or Worse at Week 36, in Anti-VEGF Incomplete Responders14.29 (6.71 to 21.87)13.51 (6.31 to 20.72)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Fisher Exact · p = 1.0000 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in percentage of participants: -0.77 · 80% CI -11.23 to 9.68The difference was calculated as Arm E minus Arm A.
SecondaryMean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants

Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · micrometres (μm)
Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants
micrometres (μm)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in Foveal Center Point Thickness at Week 36, as Measured by Spectral Domain Optical Coherence Tomography (SD-OCT), in Treatment-Naive Participants-194.00 (-207.01 to -181.00)-181.35 (-196.90 to -165.81)-193.12 (-209.49 to -176.76)-161.20 (-176.15 to -146.25)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.3798 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 12.65 · 80% CI -5.81 to 31.11The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.9529 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 0.88 · 80% CI -18.3 to 20.03The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.0208 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 32.81 · 80% CI 14.65 to 50.96The mean difference was calculated as Arm D minus Arm A.
SecondaryMean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders

Foveal center point thickness (FCPT) is defined as the thickness from the inner limiting membrane to the retinal pigment epithelial at the horizontal slice closest to the center of the fovea. Foveal center point thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Weeks 12 and 36
Reported as:
Least squares mean · micrometres (μm)
Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders
micrometres (μm)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in Foveal Center Point Thickness at Week 36, as Measured by SD-OCT, in Anti-VEGF Incomplete Responders-14.5 (-28.7 to -0.2)-20.8 (-34.5 to -7.1)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.5185 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -6.35 · 80% CI -19.0 to 6.27The mean difference was calculated as Arm E minus Arm A.
SecondaryMean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants

Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · micrometres (μm)
Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants
micrometres (μm)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in Central Subfield Thickness at Week 36, as Measured by SD-OCT, in Treatment-Naive Participants-176.18 (-188.94 to -163.43)-156.73 (-171.85 to -141.61)-173.40 (-189.40 to -157.40)-147.66 (-162.27 to -133.05)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.1624 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 19.45 · 80% CI 1.61 to 37.29The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.8475 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 2.79 · 80% CI -15.8 to 21.37The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.0381 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 28.52 · 80% CI 10.93 to 46.11The mean difference was calculated as Arm D minus Arm A.
SecondaryMean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders

Central subfield thickness (CST) is defined as the mean thickness from the inner limiting membrane to the retinal pigment epithelial over the 1 millimetre (mm) central subfield. Central subfield thickness was measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center. This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Weeks 12 and 36
Reported as:
Least squares mean · micrometres (μm)
Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders
micrometres (μm)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in Central Subfield Thickness at Week 36, as Measured by SD-OCT in Anti-VEGF Incomplete Responders-17.00 (-33.12 to -0.88)-31.42 (-46.83 to -16.02)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.2089 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -14.4 · 80% CI -29.1 to 0.29The mean difference was calculated as Arm E minus Arm A.
SecondaryNumber of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants

The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

Time frame:
Baseline, Week 36
Reported as:
Count of participants · Participants
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Treatment-Naive Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Cysts: Present at Baseline52292938
Cysts: Present at Week 36137611
Cysts: Absent at Week 3636182125
Intraretinal Fluid: Present at Baseline67463945
Intraretinal Fluid: Present at Week 3646272834
Intraretinal Fluid: Absent at Week 36181399
Pigment Epithelial Detachment: Present at Baseline58372736
Pigment Epithelial Detachment: Present at Week 3643252032
Pigment Epithelial Detachment: Absent at Week 3612664
Subretinal Fluid: Present at Baseline56413035
Subretinal Fluid: Present at Week 36111838
Subretinal Fluid: Absent at Week 3642182625
SecondaryNumber of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders

The presence of cysts, intraretinal fluid, pigment epithelial detachment, or subretinal fluid, as per the study's dry retina definition, were evaluated as individual dry retina outcomes. Cysts were defined as the presence of cystoid space (fluid) in the retina. Intraretinal fluid was defined as the presence of fluid within the retina. Pigment epithelial detachment was defined as the presence of a detachment of the pigment epithelium from the Bruch's membrane. Subretinal fluid was defined as the presence of fluid between the retina and the retinal pigment epithelium. All parameters were measured using spectral domain optical coherence tomography (SD-OCT). Anatomic outcome measures were based on results from a central reading center.

Time frame:
Weeks 12 and 36
Reported as:
Count of participants · Participants
Number of Participants With Resolution of Dry Retina at Week 36, Defined as Absence of Cysts, Intraretinal Fluid, Pigment Epithelial Detachment, or Subretinal Fluid as Measured by SD-OCT, in Anti-VEGF Incomplete Responders
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Cysts: Present at Week 12911
Cysts: Present at Week 3645
Cysts: Absent at Week 3656
Intraretinal Fluid: Present at Week 122836
Intraretinal Fluid: Present at Week 361928
Intraretinal Fluid: Absent at Week 3677
Pigment Epithelial Detachment: Present at Week 122428
Pigment Epithelial Detachment: Present at Week 361922
Pigment Epithelial Detachment: Absent at Week 3635
Subretinal Fluid: Present at Week 12109
Subretinal Fluid: Present at Week 3632
Subretinal Fluid: Absent at Week 3656
SecondaryMean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants

The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · millimetres squared (mm^2)
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by Fundus Fluorescein Angiography (FFA), in Treatment-Naive Participants-3.41 (-4.34 to -2.49)-3.81 (-4.93 to -2.70)-3.19 (-4.29 to -2.08)-3.31 (-4.31 to -2.30)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.6717 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -0.40 · 80% CI -1.61 to 0.81The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.8131 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 0.23 · 80% CI -1.01 to 1.47The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.9069 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 0.11 · 80% CI -1.07 to 1.29The mean difference was calculated as Arm D minus Arm A.
SecondaryMean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

The total area of choroidal neovascularization (CNV) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Weeks 12 and 36
Reported as:
Mean · millimetres squared (mm^2)
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders-0.50 ± 2.37-1.37 ± 3.72
SecondaryMean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants

The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · millimetres squared (mm^2)
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Treatment-Naive Participants-4.18 (-5.09 to -3.27)-5.14 (-6.24 to -4.04)-2.96 (-4.09 to -1.82)-3.83 (-4.84 to -2.82)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.3189 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -0.96 · 80% CI -2.20 to 0.28The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.2256 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 1.22 · 80% CI -0.07 to 2.52The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.7086 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 0.35 · 80% CI -0.86 to 1.57The mean difference was calculated as Arm D minus Arm A.
SecondaryMean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

The total area of choroidal neovascularization (CNV) component (i.e., total area of CNV membrane) was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Weeks 12 and 36
Reported as:
Mean · millimetres squared (mm^2)
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in Total Area of Choroidal Neovascularization (CNV) Component at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders-1.87 ± 4.05-1.88 ± 3.98
SecondaryMean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants

The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA). This analysis used a Mixed Effects Model for Repeated Measurements (MMRM). Missing data were implicitly imputed by the MMRM, assuming a missing-at-random mechanism.

Time frame:
Baseline, Week 36
Reported as:
Least squares mean · millimetres squared (mm^2)
Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 Weeks
Mean Change From Baseline in Total Area of Leakage at Week 36, as Measured by FFA, in Treatment-Naive Participants-5.15 (-6.10 to -4.20)-5.94 (-7.10 to -4.77)-3.71 (-4.88 to -2.53)-4.66 (-5.70 to -3.61)
Statistical analysis
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm B: Faricimab, 1.5 mg Q4W · Mixed Model for Repeated Measures · p = 0.4353 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: -0.78 · 80% CI -2.07 to 0.51The mean difference was calculated as Arm B minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm C: Faricimab, 6 mg Q4W · Mixed Model for Repeated Measures · p = 0.1652 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 1.45 · 80% CI 0.11 to 2.78The mean difference was calculated as Arm C minus Arm A.
  • Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W) vs Arm D: Faricimab, 6 mg Every 4-8 Weeks · Mixed Model for Repeated Measures · p = 0.61111 (The threshold for statistical significance was an unadjusted 2-sided p-value \<0.2. There was no formal correction for multiple comparisons.) · Difference in least squares means: 0.50 · 80% CI -0.76 to 1.75The mean difference was calculated as Arm D minus Arm A.
SecondaryMean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders

The total area of leakage was evaluated by a central reading center using fundus fluorescein angiography (FFA).

Time frame:
Weeks 12 and 36
Reported as:
Mean · millimetres squared (mm^2)
Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders
millimetres squared (mm^2)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Mean Change From Week 12 in Total Area of Leakage at Week 36, as Measured by FFA, in Anti-VEGF Incomplete Responders-1.87 ± 4.05-2.00 ± 3.98
SecondarySafety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants

This safety summary reports the number and percentage of participants who experienced at least one adverse event (AE) during the study. AEs are categorized as any AEs, ocular AEs occurring in the study eye or fellow eye, systemic AEs, serious AEs, AEs related to treatment with study drug, AEs leading to discontinuation (withdrawal) of treatment with study drug, and AEs with fatal outcome. The investigator independently assessed the seriousness and severity for each AE. Severity was graded according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Severity and seriousness are not synonymous; regardless of severity, some AEs may have also met seriousness criteria.

Time frame:
From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Safety Summary of the Overall Number of Participants With at Least One Adverse Event by Event Type, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Any Adverse Event (AE)5139313954
Ocular AE in Either Eye3925232937
Ocular AE in the Study Eye2821212728
Ocular AE in the Fellow Eye211691820
Serious Ocular AE in the Study Eye03002
Ocular AE in Study Eye Leading to Withdrawal01004
Systemic AE3737233043
Serious Systemic AE97746
Systemic AE Leading to Withdrawal12002
AE with Fatal Outcome00001
Any Serious AE911758
Any Related Serious AE01000
Any Related AE34330
Related Ocular AE in the Study Eye34330
Related Systemic AE00000
SecondaryNumber of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants

The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

Time frame:
From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Ocular Adverse Event in the Study Eye or the Fellow Eye by Highest Intensity, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Study Eye - Adverse Event (AE) of Any Grade2821212728
Study Eye - Mild AE2719202524
Study Eye - Moderate AE42368
Study Eye - Severe AE03002
Fellow Eye - AE of Any Grade211691820
Fellow Eye - Mild AE151471717
Fellow Eye - Moderate AE51412
Fellow Eye - Severe AE11002
SecondaryNumber of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants

The investigator assessed adverse event severity according to the following grading scale: Mild = Discomfort noticed, but no disruption of normal daily activity; Moderate = Discomfort sufficient to reduce or affect normal daily activity; Severe = Incapacitating with inability to work or to perform normal daily activity. Only the most severe intensity was counted for multiple occurrences of the same adverse event per participant at the preferred term level. Severity and seriousness are not synonymous; regardless of severity, some adverse events may have also met seriousness criteria.

Time frame:
From Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With at Least One Systemic Adverse Event by Highest Intensity, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Any Grade3737233043
Mild3027172328
Moderate1618141326
Severe72544
SecondaryNumber of Participants With Abnormal Systolic Blood Pressure, in All Participants

Abnormal systolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<70 (low) to \>140 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Time frame:
Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Systolic Blood Pressure, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Low00000
High2013132325
SecondaryNumber of Participants With Abnormal Diastolic Blood Pressure, in All Participants

Abnormal diastolic blood pressure (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>90 (high) millimetres of mercury (mmHg). Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Time frame:
Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Diastolic Blood Pressure, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Low00000
High1598109
SecondaryNumber of Participants With Abnormal Heart Rate, in All Participants

Abnormal heart rate (supine) was defined as any value outside of the standard reference range, from \<40 (low) to \>100 (high) beats per minute. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Time frame:
Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Heart Rate, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Low10100
High10111
SecondaryNumber of Participants With Abnormal Body Temperature, in All Participants

Abnormal body temperature (supine) was defined as any value outside of the standard reference range, from \<36.5 (low) to \>37.5 (high) degrees Celsius. Baseline was defined as the last non-missing predose assessment. Not every abnormal vital sign qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy.

Time frame:
Assessed at each study visit from Baseline until 28 days after the last dose of study treatment (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Body Temperature, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Low2819142529
High41126
SecondaryNumber of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants

Clinical laboratory tests for hematology and coagulation parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. Abs. = absolute count; Corp. = corpuscular; Ery. = erythrocyte; INR = International Normalized Ratio

Time frame:
Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Marked Laboratory Abnormalities in Hematology and Coagulation Tests, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Basophils, Abs., High - Any Abnormality10000
Basophils, Abs., High - Single, Not Last10000
Basophils, Abs., High - Last or Replicated00000
Eosinophils, Abs., High - Any Abnormality00030
Eosinophils, Abs., High - Single, Not Last00010
Eosinophils, Abs., High - Last or Replicated00020
Ery. Mean Corp. Volume, Low - Any Abnormality00010
Ery. Mean Corp. Volume, Low - Single, Not Last00010
Ery. Mean Corp. Volume, Low - Last or Replicated00000
Hematocrit, Low - Any Abnormality10100
Hematocrit, Low - Single, Not Last10100
Hematocrit, Low - Last or Replicated00000
Hemoglobin, Low - Any Abnormality30122
Hemoglobin, Low - Single, Not Last20001
Hemoglobin, Low - Last or Replicated10121
Lymphocytes, Abs., Low - Any Abnormality01121
Lymphocytes, Abs., Low - Single, Not Last01101
Lymphocytes, Abs., Low - Last or Replicated00020
Lymphocytes, Abs., High - Any Abnormality00010
Lymphocytes, Abs., High - Single, Not Last00000
Lymphocytes, Abs., High - Last or Replicated00010
Lymphocytes, Pct., Low - Any Abnormality01000
Lymphocytes, Pct., Low - Single, Not Last01000
Lymphocytes, Pct., Low - Last or Replicated00000
Neutrophils, Total, Abs., Low - Any Abnormality01231
Neutrophils, Total, Abs., Low - Single, Not Last01110
Neutrophils, Total, Abs., Low - Last or Replicated00121
Neutrophils, Total, Abs., High - Any Abnormality21002
Neutrophils, Total, Abs., High - Single, Not Last10002
Neutrophils, Total, Abs., High -Last or Replicated11000
Platelets, Low - Any Abnormality00021
Platelets, Low - Single, Not Last00010
Platelets, Low - Last or Replicated00011
White Blood Cell Count, Low - Any Abnormality00011
White Blood Cell Count, Low - Single, Not Last00011
White Blood Cell Count, Low - Last or Replicated00000
White Blood Cell Count, High - Any Abnormality00010
White Blood Cell Count, High - Single, Not Last00000
White Blood Cell Count, High - Last or Replicated00010
INR, High - Any Abnormality00010
INR, High - Single, Not Last00000
INR, High - Last or Replicated00010
SecondaryNumber of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants

Clinical laboratory tests for blood chemistry parameters were performed and any marked abnormal values (High or Low) were based on Roche's predefined standard reference ranges. Marked laboratory abnormalities are presented according to COG3007 abnormality criteria: Single, Not Last = abnormality detected at a single assessment, but not at the last assessment; Last or Replicated = abnormality detected at the last assessment or replicated at one or more assessments. Not every laboratory abnormality qualified as an adverse event, only if it met any of the following criteria: clinically significant (per investigator); accompanied by clinical symptoms; resulted in a change in study treatment; or required a change in concomitant therapy. GGT = gamma-glutamyltransferase; SGOT/AST = serum glutamic oxaloacetic transaminase / aspartate aminotransferase; SGPT/ALT = serum glutamic pyruvic transaminase / alanine aminotransferase

Time frame:
Predose at Baseline, Weeks 12 and 36, and at Early Termination and Unscheduled Visits (up to 36 weeks)
Reported as:
Count of participants · Participants
Number of Participants With Marked Laboratory Abnormalities in Blood Chemistry Tests, in All Participants
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Alkaline Phosphatase, High - Any Abnormality00100
Alkaline Phosphatase, High - Single, Not Last00100
Alkaline Phosphatase, High - Last or Replicated00000
Bicarbonate (CO2), Low - Any Abnormality11011
Bicarbonate (CO2), Low - Single, Not Last00010
Bicarbonate (CO2), Low - Last or Replicated11001
Bicarbonate (CO2), High - Any Abnormality53134
Bicarbonate (CO2), High - Single, Not Last30102
Bicarbonate (CO2), High - Last or Replicated23032
Calcium, Low - Any Abnormality01000
Calcium, Low - Single, Not Last00000
Calcium, Low - Last or Replicated01000
Calcium, High - Any Abnormality00001
Calcium, High - Single, Not Last00001
Calcium, High - Last or Replicated00000
Chloride, Low - Any Abnormality11002
Chloride, Low - Single, Not Last11000
Chloride, Low - Last or Replicated00002
Creatine Kinase, High - Any Abnormality20132
Creatine Kinase, High - Single, Not Last00011
Creatine Kinase, High - Last or Replicated20121
Creatinine, High - Any Abnormality01000
Creatinine, High - Single, Not Last01000
Creatinine, High - Last or Replicated00000
GGT, High - Any Abnormality00011
GGT, High - Single, Not Last00000
GGT, High - Last or Replicated00011
Phosphorus, Low - Any Abnormality01101
Phosphorus, Low - Single, Not Last01000
Phosphorus, Low - Last or Replicated00101
Phosphorus, High - Any Abnormality23215
Phosphorus, High - Single, Not Last11113
Phosphorus, High - Last or Replicated12102
Potassium, High - Any Abnormality21001
Potassium, High - Single, Not Last10000
Potassium, High - Last or Replicated11001
Protein, Total, High - Any Abnormality01000
Protein, Total, High - Single, Not Last01000
Protein, Total, High - Last or Replicated00000
SGOT/AST, High - Any Abnormality00101
SGOT/AST, High - Single, Not Last00101
SGOT/AST, High - Last or Replicated00000
SGPT/ALT, High - Any Abnormality10101
SGPT/ALT, High - Single, Not Last00101
SGPT/ALT, High - Last or Replicated10000
SecondaryMean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants

Intraocular pressure is the fluid pressure inside the eye. The method used to measure intraocular pressure (e.g., Goldmann tonometry) for each participant was to be applied consistently by the investigator throughout the study. On the day of dosing, intraocular pressure was monitored at 30 minutes post-treatment administration, and if intraocular pressure was ≥30 mmHg in the study eye, it was reassessed at 1 hour post-treatment administration.

Time frame:
Baseline, 0.5 hours postdose on Day 1, predose and 0.5 hours postdose at Weeks 4, 8, 12, 16, 20, 24, 28, and 32, and at Weeks 1, 13, and 36
Reported as:
Mean · millimetres of mercury (mmHg)
Mean Change From Baseline in Intraocular Pressure in the Study Eye Over Time, in All Participants
millimetres of mercury (mmHg)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Baseline (BL): Absolute Value15.07 ± 3.3814.74 ± 3.0814.69 ± 3.8514.98 ± 2.9114.27 ± 2.80
Change from BL at Day 1 (0.5 hr)1.90 ± 4.802.04 ± 5.321.59 ± 4.302.37 ± 4.223.52 ± 4.79
Change from BL at Week 1-0.89 ± 3.52-0.98 ± 3.47-0.62 ± 3.35-1.96 ± 2.980.11 ± 2.36
Change from BL at Week 4 (Predose)-0.27 ± 3.16-1.40 ± 2.61-1.18 ± 3.85-0.87 ± 2.990.59 ± 2.49
Change from BL at Week 4 (0.5 hr)2.88 ± 4.452.70 ± 3.562.05 ± 4.261.51 ± 3.963.59 ± 4.39
Change from BL at Week 8 (Predose)-0.56 ± 3.85-0.32 ± 3.13-0.69 ± 3.07-0.87 ± 2.750.10 ± 2.64
Change from BL at Week 8 (0.5 hr)2.70 ± 4.212.59 ± 4.642.37 ± 5.151.93 ± 3.913.93 ± 4.52
Change from BL at Week 12 (Predose)-0.17 ± 3.49-0.02 ± 2.88-0.82 ± 3.370.13 ± 2.940.45 ± 2.45
Change from BL at Week 12 (0.5 hr)3.08 ± 4.012.43 ± 3.412.59 ± 3.952.11 ± 4.044.34 ± 5.25
Change from BL at Week 13-0.77 ± 3.27-0.68 ± 3.12-0.71 ± 4.02-1.09 ± 2.70-0.65 ± 2.75
Change from BL at Week 16 (Predose)-0.41 ± 3.390.02 ± 3.10-0.77 ± 3.11-1.00 ± 2.56-0.36 ± 2.83
Change from BL at Week 16 (0.5 hr)1.64 ± 4.621.95 ± 5.351.67 ± 3.92-0.30 ± 3.983.12 ± 5.27
Change from BL at Week 20 (Predose)-0.16 ± 3.02-1.00 ± 2.730.08 ± 3.61-0.44 ± 3.18-0.17 ± 2.71
Change from BL at Week 20 (0.5 hr)2.80 ± 4.811.74 ± 4.851.82 ± 5.370.68 ± 5.452.62 ± 4.54
Change from BL at Week 24 (Predose)0.00 ± 3.29-0.33 ± 3.300.26 ± 2.77-0.61 ± 2.730.14 ± 2.73
Change from BL at Week 24 (0.5 hr)3.23 ± 3.913.26 ± 4.044.11 ± 3.510.91 ± 3.664.17 ± 4.28
Change from BL at Week 28 (Predose)-0.02 ± 2.800.00 ± 4.30-1.00 ± 2.91-0.38 ± 2.74-0.19 ± 2.89
Change from BL at Week 28 (0.5 hr)3.16 ± 4.282.90 ± 4.131.74 ± 4.802.53 ± 3.603.86 ± 4.49
Change from BL at Week 32 (Predose)-0.73 ± 3.72-0.23 ± 3.63-0.41 ± 3.07-0.80 ± 2.92-0.67 ± 3.06
Change from BL at Week 32 (0.5 hr)1.81 ± 5.103.87 ± 5.581.63 ± 5.47-0.98 ± 4.382.37 ± 4.97
Change from BL at Week 360.00 ± 3.300.25 ± 3.68-0.65 ± 3.85-0.20 ± 3.55-0.16 ± 3.18
SecondaryChange From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint

Blood samples were obtained for measurement of anti-faricimab antibodies by a validated enzyme-linked immunosorbent assay (ELISA).

Time frame:
Baseline, Predose (0 hour) on Days 1, 28, 84, 112, 168, and 252 or early termination (up to 36 weeks)
Reported as:
Count of participants · Participants
Change From Baseline in the Number of Participants With Anti-Drug Antibodies to Faricimab at Any Post-Baseline Timepoint
ParticipantsArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
ADA Negative to Missing—1000
ADA Negative to ADA Negative—41353654
ADA Negative to ADA Positive—3396
ADA Positive to Missing—0000
ADA Positive to ADA Negative—1000
ADA Positive to ADA Positive—0013
SecondaryMean Plasma Concentration of Faricimab Over Time, in All Participants

Plasma concentrations of faricimab were measured by a specific validated enzyme-linked immunoabsorbent assay (ELISA) only from samples of participants randomized to receive faricimab. Baseline was defined as the last non-missing predose assessment. The lower limit of quantification (LLOQ) for the faricimab assay was 0.800 nanograms per millilitre (ng/mL). Values below the limit of quantification were imputed as LLOQ divided by 2.

Time frame:
Predose (on days when treatment was administered) at Baseline and Weeks 4, 12, 13, 16, 24, and 36
Reported as:
Mean · nanograms per millilitre (ng/mL)
Mean Plasma Concentration of Faricimab Over Time, in All Participants
nanograms per millilitre (ng/mL)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Baseline—0.40 ± 0.000.40 ± 0.000.40 ± 0.000.47 ± 0.59
Week 4—8.83 ± 5.8531.06 ± 18.4736.58 ± 19.78—
Week 12—18.68 ± 24.3857.92 ± 57.6557.94 ± 73.9145.29 ± 105.64
Week 13—43.32 ± 31.98184.38 ± 102.01178.25 ± 119.98160.52 ± 124.73
Week 16—9.52 ± 7.4146.99 ± 35.1943.54 ± 39.0544.71 ± 50.55
Week 24—9.07 ± 7.3935.30 ± 22.0331.19 ± 24.1337.80 ± 27.75
Week 36—10.65 ± 8.4736.43 ± 30.804.69 ± 7.2436.06 ± 26.93
SecondaryMean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants

The concentration of free VEGF was determined in plasma samples using an enzyme-linked immunosorbent assay (ELISA) method. The lower limit of quantification (LLOQ) of the assay was 15.6 picograms per millilitre (pg/mL). Plasma free VEGF concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Time frame:
Baseline, Weeks 4, 12, 13, 16, 24, and 36
Reported as:
Mean · picograms per millilitre (pg/mL)
Mean Change From Baseline in Free Vascular Endothelial Growth Factor-A (VEGF-A) Plasma Concentrations Over Time, in All Participants
picograms per millilitre (pg/mL)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Baseline (BL) - Value at Visit15.25 ± 10.6016.83 ± 12.0824.63 ± 31.4716.53 ± 9.7322.60 ± 27.79
Change from BL at Week 40.52 ± 12.203.94 ± 33.25-9.26 ± 27.76-0.62 ± 15.673.75 ± 53.99
Change from BL at Week 121.52 ± 19.45-0.46 ± 13.30-8.58 ± 20.73-4.70 ± 11.79-3.24 ± 27.79
Change from BL at Week 132.62 ± 21.695.47 ± 52.19-14.10 ± 33.55-7.36 ± 10.67-15.14 ± 33.85
Change from BL at Week 1612.12 ± 67.43-3.28 ± 10.61-9.86 ± 33.05-6.28 ± 10.84-5.34 ± 32.90
Change from BL at Week 24-0.67 ± 10.4510.35 ± 50.09-12.57 ± 31.86-5.20 ± 10.07-7.19 ± 31.54
Change from BL at Week 361.91 ± 28.59-0.79 ± 11.86-12.16 ± 32.48-1.34 ± 13.69-8.17 ± 29.73
SecondaryMean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants

Total Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.09 nanograms per millilitre (ng/mL). Plasma total Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Time frame:
Baseline, Weeks 4, 12, 13, 16, 24, and 36
Reported as:
Mean · nanograms per millilitre (ng/mL)
Mean Change From Baseline in Total Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants
nanograms per millilitre (ng/mL)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Baseline (BL) - Value at Visit2.14 ± 1.381.81 ± 0.671.86 ± 1.121.80 ± 0.711.92 ± 0.95
Change from BL at Week 40.03 ± 0.480.09 ± 0.390.09 ± 0.270.20 ± 0.49-0.03 ± 0.38
Change from BL at Week 120.10 ± 0.890.14 ± 0.370.22 ± 0.480.19 ± 0.50-0.11 ± 0.49
Change from BL at Week 130.18 ± 0.910.23 ± 0.351.05 ± 1.150.87 ± 0.760.81 ± 0.98
Change from BL at Week 160.01 ± 0.620.04 ± 0.710.24 ± 0.470.22 ± 0.61-0.01 ± 0.52
Change from BL at Week 240.00 ± 0.680.11 ± 0.770.21 ± 0.520.24 ± 0.570.04 ± 0.44
Change from BL at Week 360.08 ± 0.420.05 ± 0.420.25 ± 0.390.33 ± 0.890.05 ± 0.56
SecondaryMean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants

Free Ang-2 concentrations were determined in plasma samples using an appropriate assay method. The lower limit of quantification (LLOQ) of the assay was 0.9 nanograms per millilitre (ng/mL). Plasma free Ang-2 concentrations below the limit of quantification were imputed as LLOQ divided by 2.

Time frame:
Baseline, Weeks 4, 12, 13, 16, 24, and 36
Reported as:
Mean · nanograms per millilitre (ng/mL)
Mean Change From Baseline in Free Angiopoietin-2 (Ang-2) Plasma Concentrations Over Time, in All Participants
nanograms per millilitre (ng/mL)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Baseline (BL) - Value at Visit2.19 ± 1.381.81 ± 0.731.88 ± 0.981.73 ± 0.751.95 ± 1.12
Change from BL at Week 40.00 ± 0.570.14 ± 0.37-0.05 ± 0.460.15 ± 0.62-0.07 ± 0.55
Change from BL at Week 120.23 ± 1.120.20 ± 0.570.12 ± 0.520.21 ± 0.75-0.01 ± 0.59
Change from BL at Week 130.03 ± 0.920.23 ± 0.690.81 ± 1.110.55 ± 0.750.32 ± 0.93
Change from BL at Week 160.06 ± 0.770.17 ± 0.950.15 ± 0.620.22 ± 0.67-0.11 ± 0.65
Change from BL at Week 240.18 ± 0.900.20 ± 0.930.25 ± 0.490.39 ± 0.580.13 ± 0.59
Change from BL at Week 360.16 ± 0.740.25 ± 0.650.28 ± 0.630.51 ± 1.300.06 ± 0.66

Adverse events

Collected over From Baseline until 28 days after the last dose of study treatment (up to 36 weeks). Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)0/67 (0%)9/67 (13.4%)39/67 (58.2%)
Arm B: Faricimab, 1.5 mg Q4W0/46 (0%)11/46 (23.9%)31/46 (67.4%)
Arm C: Faricimab, 6 mg Q4W0/39 (0%)7/39 (17.9%)24/39 (61.5%)
Arm D: Faricimab, 6 mg Every 4-8 Weeks0/46 (0%)5/46 (10.9%)32/46 (69.6%)
Arm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W1/64 (1.6%)8/64 (12.5%)40/64 (62.5%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Acute myocardial infarctionCardiac disorders0/670/461/390/460/64
Atrial fibrillationCardiac disorders0/670/461/391/460/64
Chest painGeneral disorders0/670/461/390/460/64
Arteriogram coronaryInvestigations0/670/461/390/460/64
NephrolithiasisRenal and urinary disorders0/670/461/390/460/64
Postmenopausal haemorrhageReproductive system and breast disorders0/670/461/390/460/64
HypertensionVascular disorders0/670/461/390/460/64
ShockVascular disorders0/670/461/390/460/64
Atrial flutterCardiac disorders0/670/460/391/460/64
Keratic PrecipitatesEye disorders0/671/460/390/460/64
Most frequent other events
Showing 10 of 57
Most frequent other events
EventArm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4W
Urinary tract infectionInfections and infestations6/6711/462/390/463/64
Conjunctival haemorrhageEye disorders14/674/466/396/466/64
NasopharyngitisInfections and infestations9/674/461/391/465/64
Eye painEye disorders2/674/462/395/463/64
Vitreous detachmentEye disorders3/675/463/395/464/64
Eye irritationEye disorders0/671/464/394/461/64
Vitreous floatersEye disorders2/673/464/393/461/64
Neovascular age-related macular degenerationEye disorders6/674/463/392/465/64
Punctate keratitisEye disorders0/670/460/390/465/64
Posterior capsule opacificationEye disorders2/671/463/390/461/64

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
Mean76.4 ± 8.978.2 ± 8.978.0 ± 9.180.0 ± 8.079.2 ± 8.378.3 ± 8.7
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
Female3932273440172
Male291412122491
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
Hispanic or Latino4304213
Not Hispanic or Latino6443384261248
Unknown or Not Reported001012
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
American Indian or Alaska Native000101
Asian000000
Native Hawaiian or Other Pacific Islander000000
Black or African American100001
White6645394464258
More than one race100001
Unknown or Not Reported010102
Best-Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline
Best-Corrected Visual Acuity (BCVA) Letter Score in the Study Eye at Baseline(BCVA Letters)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
Mean55.2 ± 12.756.7 ± 11.156.2 ± 12.256.3 ± 11.555.7 ± 11.655.9 ± 11.9
Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline
Best-Corrected Visual Acuity (BCVA) Letter Score Category in the Study Eye at Baseline(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
BCVA Letter Score ≤542220152126104
BCVA Letter Score >544526242538158
Assessment Missing100001
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline
Choroidal Neovascularization (CNV) Lesion Type in the Study Eye at Baseline(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
Classic & Occult CNV261912202198
Classic CNV86761037
Occult CNV3320201933125
Assessment Missing110103
Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline
Presence or Absence of Retinal Angiomatous Proliferation (RAP) in the Study Eye at Baseline(Participants)Arm A: Ranibizumab, 0.5 mg Every 4 Weeks (Q4W)Arm B: Faricimab, 1.5 mg Q4WArm C: Faricimab, 6 mg Q4WArm D: Faricimab, 6 mg Every 4-8 WeeksArm E: Ranibizumab 0.5 mg + Faricimab 6 mg Q4WTotal
RAP Absent4430292947179
RAP Present22149141675
Assessment Missing221319

1 further baseline measures are reported on the registry.

08

Study locations

52 sites
  • Associated Retina Consultants
    Phoenix, Arizona 85020, United States
  • Retinal Consultants of Arizona
    Phoenix, Arizona 85053, United States
  • California Retina Consultants
    Bakersfield, California 93309, United States
  • Retina-Vitreous Associates Medical Group
    Beverly Hills, California 90211, United States
  • The Retina Partners
    Encino, California 91436, United States
  • Retina Consultants, San Diego
    Poway, California 92064, United States
  • Orange County Retina Med Group
    Santa Ana, California 92705, United States
  • Bay Area Retina Associates
    Walnut Creek, California 94598, United States
  • American Institute of Research
    Whittier, California 90603, United States
  • Retina Consultants of Southern
    Colorado Springs, Colorado 80909, United States
  • Colorado Retina Associates, PC
    Golden, Colorado 80401, United States
  • New England Retina Associates
    Hamden, Connecticut 06518, United States
  • Retina Health Center
    Fort Myers, Florida 33907, United States
  • National Ophthalmic Research Institute
    Fort Myers, Florida 33912, United States
  • Florida Eye Associates
    Melbourne, Florida 32901, United States
  • Central Florida Retina
    Orlando, Florida 32806, United States
  • Retina Care Specialists
    Palm Beach Gardens, Florida 33410, United States
  • Retina Vitreous Assoc of FL
    Saint Petersburg, Florida 33711, United States
  • Southern Vitreoretinal Assoc
    Tallahassee, Florida 32308, United States
  • Southeast Retina Center
    Augusta, Georgia 30909, United States
  • Georgia Retina PC
    Marietta, Georgia 30060, United States
  • Midwest Eye Institute Northside
    Indianapolis, Indiana 46290, United States
  • Paducah Retinal Center
    Paducah, Kentucky 42001, United States
  • Retina Group of Washington
    Chevy Chase, Maryland 20815, United States
  • National Retina Institute
    Towson, Maryland 21204, United States
  • Vitreo-Retinal Associates, PC
    Worcester, Massachusetts 01605, United States
  • Vitreoretinal Surgery
    Edina, Minnesota 55435, United States
  • Retina Associates of NJ
    Toms River, New Jersey 08755, United States
  • Eye Associates of New Mexico
    Albuquerque, New Mexico 87102, United States
  • Long Is. Vitreoretinal Consult
    Great Neck, New York 11021, United States
  • Opthalmic Consultants of LI
    Lynbrook, New York 11563, United States
  • Retina Assoc of Western NY
    Rochester, New York 14620, United States
  • The Retina Consultants
    Slingerlands, New York 12159, United States
  • Western Carolina Retinal Associate PA
    Asheville, North Carolina 28803, United States
  • Char Eye Ear &Throat Assoc
    Charlotte, North Carolina 28210, United States
  • OSU Eye Physicians & Surgeons
    Columbus, Ohio 43212, United States
  • Oregon Retina, LLP
    Eugene, Oregon 97401, United States
  • Oregon Retina institute
    Medford, Oregon 97504, United States
  • Retina Northwest
    Portland, Oregon 97221, United States
  • Mid Atlantic Retina
    Philadelphia, Pennsylvania 19107, United States
  • Palmetto Retina Center
    West Columbia, South Carolina 29169, United States
  • Southeastern Retina Associates Chattanooga
    Chattanooga, Tennessee 37421, United States
  • Charles Retina Institute
    Germantown, Tennessee 38138, United States
  • Tennessee Retina PC.
    Nashville, Tennessee 37203, United States
  • W Texas Retina Consultants PA
    Abilene, Texas 79606, United States
  • Austin Retina Associates
    Austin, Texas 78705, United States
  • Retina Research Center
    Austin, Texas 78705, United States
  • Retina Consultants of Houston
    Houston, Texas 77030, United States
  • Strategic Clinical Research Group, LLC
    Willow Park, Texas 76087, United States
  • Retina Associates of Utah
    Salt Lake City, Utah 84107, United States
  • Univ of Virginia Ophthalmology
    Charlottesville, Virginia 22903, United States
  • Spokane Eye Clinical Research
    Spokane, Washington 99204, United States
09

References and documents

Publications

  • Maunz A, Benmansour F, Li Y, Albrecht T, Zhang YP, Arcadu F, Zheng Y, Madhusudhan S, Sahni J. Accuracy of a Machine-Learning Algorithm for Detecting and Classifying Choroidal Neovascularization on Spectral-Domain Optical Coherence Tomography. J Pers Med. 2021 Jun 8;11(6):524. doi: 10.3390/jpm11060524. PubMed 34201045 ↗
  • Sahni J, Dugel PU, Patel SS, Chittum ME, Berger B, Del Valle Rubido M, Sadikhov S, Szczesny P, Schwab D, Nogoceke E, Weikert R, Fauser S. Safety and Efficacy of Different Doses and Regimens of Faricimab vs Ranibizumab in Neovascular Age-Related Macular Degeneration: The AVENUE Phase 2 Randomized Clinical Trial. JAMA Ophthalmol. 2020 Sep 1;138(9):955-963. doi: 10.1001/jamaophthalmol.2020.2685. PubMed 32729888 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Sep 2017, 25 months.

Results were first posted in Oct 2020, 3 years after primary completion. A results delay was requested in Sep 2018.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2015
First posted
Jun 30, 2015
StartActual
Aug 11, 2015
Primary completionActual
Sep 26, 2017
CompletionActual
Sep 26, 2017
Results delay requested
Sep 25, 2018
Results first posted
Oct 9, 2020
Last update
Nov 12, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02484690
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 30, 2015
Start date
Aug 11, 2015
Primary completion
Sep 26, 2017
Completion
Sep 26, 2017
Results posted
Oct 9, 2020
Last update
Nov 12, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Faricimab · Ranibizumab

Start the discussion